Multilocus Heterozygosity and Coronary Heart Disease: Nested Case-Control Studies in Men and Women by Mukamal, Kenneth J. et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 21, 2017
Multilocus Heterozygosity and Coronary Heart Disease: Nested Case-Control Studies
in Men and Women
Mukamal, Kenneth J.; Jensen, Majken K.; Pers, Tune Hannes; Pai, Jennifer K.; Kraft, Peter; Rimm, Eric B.
Published in:
PLOS ONE
Link to article, DOI:
10.1371/journal.pone.0124847
Publication date:
2015
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Mukamal, K. J., Jensen, M. K., Pers, T. H., Pai, J. K., Kraft, P., & Rimm, E. B. (2015). Multilocus Heterozygosity
and Coronary Heart Disease: Nested Case-Control Studies in Men and Women. PLOS ONE, 10(5), [e0124847].
DOI: 10.1371/journal.pone.0124847
RESEARCH ARTICLE
Multilocus Heterozygosity and Coronary
Heart Disease: Nested Case-Control Studies
in Men and Women
Kenneth J. Mukamal1*, Majken K. Jensen2, Tune H. Pers3,4,5,6,7, Jennifer K. Pai2,8,
Peter Kraft9,10, Eric B. Rimm2,8,9
1 Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of
America, 2 Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, United States
of America, 3 Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark,
4 Division of Genetics, Children's Hospital, Boston, Massachusetts, United States of America, 5 Division of
Endocrinology, Children's Hospital, Boston, Massachusetts, United States of America, 6 Medical and
Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America, 7 Institute of
Preventive Medicine, Copenhagen University Hospital, Copenhagen, Denmark, 8 Channing Division of
Network Medicine, Department of Medicine, Brigham andWomen's Hospital and Harvard Medical School,
Boston, Massachusetts, United States of America, 9 Department of Epidemiology, Harvard School of Public
Health, Boston, Massachusetts, United States of America, 10 Department of Biostatistics, Harvard School of
Public Health, Boston, Massachusetts, United States of America
* kmukamal@bidmc.harvard.edu
Abstract
Background
Generalized allelic heterozygosity has been proposed to improve reproductive fitness and
has been associated with higher blood pressure, but its association with chronic disease is
not well characterized.
Methods
Using the Affymetrix Genome-Wide Human 6.0 array, we performed whole genome scans
in parallel case-control studies of coronary heart disease (CHD) nested in the Health Pro-
fessionals Follow-up Study and Nurses’Health Study. We examined ~700,000 single nucle-
otide polymorphisms (SNPs) in 435 men with incident CHD and 878 matched controls and
435 women with incident CHD with 931 matched controls. We examined the relationship of
genome-wide heterozygosity with risk of incident of CHD and with baseline levels of cardio-
vascular risk factors.
Results
In both cohorts, approximately 227650 (SD 2000) SNPs were heterozygous. The number of
heterozygous SNPs was not related to risk of CHD in either men or women (adjusted odds
ratios per 2000 heterozygous SNPs 1.01 [95% confidence interval, 0.91-1.13] in women
and 0.94 [0.84-1.06] in men). We also found no consistent associations of genome-wide
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Conclusions
In these parallel nested case-control studies, we found no relationship of multilocus hetero-
zygosity with risk of CHD or its major risk factors. Studies in other populations are needed to
rule out associations with lower levels of heterozygosity.
Introduction
Although individual humans share some 99.6% of base pairs with others,[1] the size of the
human genome dictates that there are nonetheless some 24 million base pairs that differ be-
tween individuals. This degree of variation offers substantial opportunity for the manifestation
of heterozygote advantage, the phenomenon of biological advantage of mixed over
pure breeds.
Multilocus heterozygosity may act in two ways. First, heterozygosity at individual loci may
provide an advantage relative to homozygote wild-type or variant alleles, sometimes referred to
as overdominance. The best known is variation in genes related to erythrocyte function, many
of which confer resistance to malaria.[2] In this setting, homozygotes are disadvantaged by ei-
ther susceptibility to malaria (for wild-type alleles) or clinical syndromes as sickle cell anemia,
thallasemia, and glucose-6-phosphate dehydrogenase deficiency. There is also evidence that
heterozygosity at specific loci may be associated with perceived attractiveness of humans to
members of the opposite sex.[3,4] Second, heterozygosity as a manifestation of outbreeding re-
duces risk of homozygosity in disadvantageous alleles, leading in the most adverse situations to
recessive diseases.
An important caveat in studies of human heterozygosity is the limited evidence that hetero-
sis confers protection against chronic disease, which is less likely to exert selection pressure
than do acute infectious diseases or attractiveness to mates, yet is the dominant cause of mor-
tality in developed nations. Heterozygosity at selected loci has been associated with extreme
longevity, but these have not been replicated and it is uncertain that they exemplify generalized
heterosis.[5,6] In a genome-wide comparison of populations in the Dalmation Islands,[7]
Campbell and colleagues found that overall heterozygosity across populations was associated
with lower blood pressure and total cholesterol, but individual heterozygosity was not mea-
sured, raising the strong possibility that this reflects population stratification. Among individu-
als in the Framingham Heart Study, multilocus heterozygosity at 706 single nucleotide
polymorphisms (SNPs) was associated with higher blood pressure, but not with several other
cardiovascular traits measured simultaneously.[8] To our knowledge, no genome-wide assess-
ment among individuals has evaluated whether heterozygosity confers an advantage on com-
mon chronic diseases among adults.
To elucidate whether heterozygote advantage extends to coronary heart disease (CHD), the
most common cause of death in the United States,[9] we determined the association of varia-
tion in genome-wide single nucleotide polymorphisms (SNPs) with both risk of incident CHD
and with several CHD risk factors in two well-characterized parallel cohorts of men
and women.
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Materials and Methods
Study Population and Design
The NHS cohort was established in 1976. The study population consists of 121,700 married fe-
male registered nurses aged 30 to 55 years residing in one of 11 larger US states. Women have
received follow-up questionnaires biennially to update information on exposures and newly di-
agnosed illnesses. Since 1980, participants have updated information on diet, alcohol, and vita-
min supplements through a food frequency questionnaire every four years.
The HPFS began in 1986, when 51,529 male health professionals 40 to 75 years of age com-
pleted the initial 6-page HPFS questionnaire. The population includes 29,683 dentists, 3,745
optometrists, 2,218 osteopathic physicians, 4,185 pharmacists, 1,600 podiatrists, and 10,098
veterinarians. Biennial follow-up has mirrored the NHS.
Case-Control Sampling
We used data from nested case-control studies of CHD in the NHS and HPFS. Blood samples
were requested from all active participants and collected from 32,826 NHS members in 1989–
1990 and 18,225 HPFS members in 1993–1994. With the exception of a modestly lower preva-
lence of smoking, those who returned blood samples did not differ substantially from those
who did not in both cohorts; mean ages at blood collection were 64 years in men and 60 in
women. Participants underwent local phlebotomy and returned samples to our laboratory via
overnight courier. Upon arrival, whole blood samples were centrifuged and stored in cryotubes
as plasma, buffy coat, and red blood cells in the vapor phase of liquid nitrogen freezers.
From within these subcohorts of women and men who provided blood samples, we con-
ducted parallel nested case-control studies of CHD, defined as non-fatal myocardial infarction
or fatal CHD. We wrote to participants who reported incident CHD on the follow-up question-
naires to confirm the report and request permission to review medical records. We also sought
medical records for deceased participants, whose deaths were identified by families and postal
officials and through the National Death Index. Physicians blinded to the participant’s ques-
tionnaire reports reviewed all medical records. Cases of myocardial infarction and fatal CHD
were confirmed through review of medical records, as previously described.[10,11]
In the NHS, we matched women free of cardiovascular disease or cancer in 1990 who sus-
tained an incident MI or fatal CHD through 2004 to two randomly selected controls on the
basis of age and smoking using risk-set sampling.[12] In the HPFS, we matched men free of
cardiovascular disease in 1994 who developed incident CHD through 2004 to 878 control men.
In this study design, a control for an early case may be included again if the person develops
CHD during follow-up; after counting such converters only once, the total number of samples
sent for genotyping were 1524 women and 1354 men.
Genotyping
In 2008, DNA was extracted for genotyping at Merck Research Laboratories, North Wales, PA,
using the Affymetrix Genome-Wide Human 6.0 array. Quality control criteria used to define
unsuccessful genotyping were a call rate<97%, sex mismatch, and Hardy-Weinberg equilibri-
um p<10–4 in controls. Analyses based on principal components were conducted to assess self-
reported race. Subsequent analysis sample was restricted to subjects of European ancestry. Self-
reported "white" samples with substantial similarity to non-European reference samples (the
HapMap Yoruba or Asian samples) were excluded. Three eigenvectors were included as covari-
ates to adjust for potential population stratification in the final sample.
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Because women with diabetes were genotyped earlier than those without using slightly dif-
ferent platforms, we excluded the ~28,000 SNPs that were not common to the platforms of
both diabetic and non-diabetic women. This left a total of 692,794 SNPs for analysis in women
and 724,881 in men.
Measurement of Risk Factor Levels
All biomarkers were measured on samples stored at -130°C and have been found to be largely
unaffected by transport conditions and reproducible within persons over time.[13,14] Mea-
surements included lipids (triglycerides, HDL, calculated LDL), inflammatory markers (C-re-
active protein, interleukin-6, fibrinogen), homocysteine, adhesion molecules (E-selectin,
intercellular adhesion molecule [ICAM]-1, vascular cell adhesion molecule [VCAM]-1) and
total and high molecular weight (HMW) adiponectin. Of these, E-selectin, HMW adiponectin,
and homocysteine were only measured in women, and IL-6, fibrinogen, homocysteine, E-selec-
tin, ICAM-1, and VCAM-1 were measured only in the initial subset of case-control pairs
among women. We also included body-mass index (BMI) based upon self-reported height and
weight, which have been found to be reliable within these cohorts.[15]
Statistical Methods
We examined the associations of multilocus heterozygosity with CHD and its risk factors in
multiple ways. Because the number of SNPs and their associated genes were identical across
genotyped individuals, we used both the overall number of heterozygous loci and the propor-
tion of loci that were heterozygous; the latter yielded essentially identical results and are not
shown here. We conducted three SNP-level analyses, evaluating all autosomal SNPs, a subset
of those within the boundaries of all human protein-coding genes and their 70kb upstream and
20kb upstream flanking regions (n = 562,289), and only nonsynonymous SNPs (n = 4,760).
Gene coordinates and nonsynonymous SNPs were retrieved from the Ensembl database ver-
sion 56.37a.
For incident CHD, we performed unconditional logistic regression with adjustment for
matching factors in all analyses; this approach yielded results similar to conditional logistic re-
gression with more consistent model convergence. We report odds ratios per 2000 SNPs for
analyses of all SNPs and SNPs within genes and per 25 SNPs for nonsynonymous SNPs; these
units reflect ~1 standard deviation in each measure.
Analyses of risk factors were conducted with mixed models, including both cases and con-
trols and adjusting for age, smoking, eigenvectors, and case-control status; this approach pro-
vides unbiased estimates when genetic risk factors are not strongly associated with case-control
status.[16] Information on allelic dosage was extracted for all SNPs using PLINK,[17] and sta-
tistical analysis were performed in SAS version 9 (SAS Institute Inc., Cary, NC).
Ethics Statement
The study protocol, including genotyping, was approved by the institutional review boards of
the Brigham andWomen’s Hospital and the Harvard School of Public Health. The completion
of the self-administered questionnaire was considered to imply informed consent; participants
who provided blood samples additionally provided written informed consent.
Results
Following cleaning of genotyping data, we included 435 women with incident CHD and 931
control women and 435 men with incident CHD and 878 control men. Table 1 demonstrates
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the associations of genome-wide heterozygosity with risk of CHD among women and men. In
both sexes, we observed no relationships of CHD with overall number of heterozygous loci,
number of heterozygous loci within genes, or number of heterozygous nonsynonymous loci.
These results were essentially identical when the proportions of heterozygous SNPs overall,
within genes, or at nonsynonymous loci were used, or when we restricted to individuals below
65 years of age at blood draw.
Table 2 shows the relationship of heterozygosity with levels of selected CHD risk factors.
There were only two modestly significant relationships in men (LDL among all SNPs and
SNPs within genes and fibrinogen among nonsynonymous SNPs; p = 0.03–0.04) and none that
were consistent in both sexes, regardless of which measure of heterozygosity was used. One
possible exception was the association of overall heterozygosity and heterozygosity within
genes with E-selectin (p = 0.03), which was only measured in women and hence could not be
confirmed or refuted in men.
Table 1. Mean (±SD) numbers of heterozygous loci among CHD cases and controls and odds ratios (95% confidence interval) for CHD associated
with heterozygous loci.
Women Men
Cases (n = 435) Controls (n = 931) p-value Cases (n = 435) Controls (n = 878) p-value
Number of heterozygous loci 227650 ±1869 227642 ±2240 0.94 227349 ±2184 227451 ±1860 0.40
Number of heterozygous loci within genes 141601 ±1314 141623 ±1471 0.78 142581 ±1452 142633 ±1276 0.53
Number of heterozygous nonsynonymous SNPs 894 ±27 895 ±27 0.58 914 ±27 912 ±27 0.23
Odds ratio of CHD per:
2000 heterozyg. loci 1.01 (0.91–1.13) Referent 0.94 (0.84–1.06) Referent
2000 heterozygous loci within genes 0.99 (0.84–1.17) Referent 0.94 (0.79–1.12) Referent
25 heterozygous nonsynonymous SNPs 0.97 (0.87–1.08) Referent 1.07 (0.96–1.19) Referent
Odds ratios adjusted for age, smoking, and population eigenvectors.
doi:10.1371/journal.pone.0124847.t001
Table 2. Association of CHD risk factors with overall heterozygous loci, loci within genes, and nonsynonymous SNPs.
Women Men
Women/Men All Within Genes Nonsynonymous All Within Genes Nonsynonymous
HDL (mg/dL) 1198/1287 -0.7 ±0.4 -0.9 ±0.6 -0.7 ±0.4 0.3 ±0.3 0.5 ±0.5 -0.08 ±0.3
LDL (mg/dL) 1181/1286 0.3 ±1.0 0.9 ±1.5 1.0 ±1.0 -1.9 ±0.9 -2.7 ± 1.3 -0.6 ±0.8
Triglycerides (mg/dL) 1131/1287 1 ±2 2 ±3 3 ±2 1 ±3 3 ±4 -2 ±3
CRP (mg/dL) 1185/1287 -0.02 ±0.02 -0.01 ±0.02 -0.03 ±0.02 -0.01 ±0.02 -0.01 ±0.02 0.001 ±0.01
IL-6 (pg/mL) 616/762 -0.4 ±0.4 -0.5 ±0.5 0.03 ±0.4 0.03 ±0.5 0.3 ±0.7 0.5 ±0.4
Fibrinogen (mg/dL) 211/762 -0.2 ±7 3 ±10 -2 ±5 -2 ±3 -3 ±4 5 ±3
Homocysteine (μmol/L) 644 -0.1 ±0.2 -0.07 ±0.3 -0.03 ±0.2
E-selectin (ng/mL) 640 1.5 ±0.8 2.7 ±1.2 0.4 ±0.8
ICAM (ng/mL) 211/762 -0.8 ±8 -2 ±11 4 ±6 -2 ±4 -0.1 ±5 -4 ±3
VCAM (ng/mL) 209/762 5 ±11 -0.3 ±16 -3 ±8 0.4 ±11 -4 ±17 -4 ±10
Total adiponectin (ng/mL) 1209/762 -20 ±106 -54 ±159 117 ±107 -194 ±318 -94 ±465 -532 ±290
HMW adiponectin (ng/mL) 1209 -3 ±85 1 ±126 85 ±85
BMI (kg/m2) 1323/1304 0.1 ±0.1 0.2 ±0.2 0.1 ±0.1 0.2 ±0.1 0.2 ±0.1 0.02 ±0.08
All estimates adjusted for age, smoking, population eigenvectors, and case-control status.
doi:10.1371/journal.pone.0124847.t002
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Discussion
In this analysis of two prospective case-control studies, we found no consistent evidence of het-
erozygosity advantage in risk for CHD. The number or proportion of heterozygous loci was
unrelated to either incident CHD or to circulating CHD risk factors.
The hypothesis of overdominance associated with heterozygosity at individual loci is attrac-
tive and has clear support in a few well-described instances. Certainly, the best recognized of
these is the selection pressure exerted by P. falciparum, which infects erythrocytes. The wide-
spread prevalence of falciparum malaria appears to have selected for hemoglobin variants that,
while disadvantageous on their own, appear to mitigate the consequences of plasmodial infec-
tion.[2] Another proposed manifestation of overdominance may exist in perceived attractive-
ness, even in non-human primate species.[18] For example, in one study, women rated the
faces of men heterozygous at three major histocompatibility complex loci as more attractive
than the faces of homozygotes, regardless of the level of genetic similarity between female raters
and male subjects.[19]
At the same time, evidence that generalized heterozygosity provides an advantage for risk of
chronic disease, and particularly for CHD, is sparse. The Framingham Heart Study reported a
positive association of heterozygosity at 706 loci with blood pressure and two related echocar-
diographic parameters among approximately 1000 participants, but no association with any
circulating risk factors or with BMI; no association with risk of CHD per se was tested.[8] Be-
cause we did not have standardized blood pressure or echocardiographic measurement in our
cohorts, we cannot directly replicate their findings, but our results do confirm the lack of asso-
ciation with a large number of putative risk factors and extend these results to clinical CHD
endpoints. Why blood pressure might differ from other risk factors in its association with het-
erosis is necessarily speculative, but it is striking that the observed association in Framingham
was positive—that is, greater heterozygosity conferred a phenotype of higher blood pressure
that might well be protective in the setting of acute primordial stressors like trauma or dehy-
dration, but could be harmful for conditions like CHD that manifest in late adulthood. Thus,
we find no clear evidence that multilocus heterozygosity is associated with a lower risk of
CHD, the most common cause of mortality in developed nations. Its associations with cancer,
dementia, and other chronic diseases remain to be tested, although recent work suggests it may
influence schizophrenia.[20]
We found few significant relationships—about the number expected from chance alone—
and unsurprisingly these generally did not appear consistent across cohorts. The exception of
E-selectin is interesting, as its genetic variation is strongly related to ABO blood group geno-
type[21] and hence could also be subjected to plasmodial selection pressure.[22] However,
there appears to be little ancestral selection pressure in erythrocyte traits among populations of
European ancestry and hence even this possible association clearly requires confirmation in
other cohorts.
Two differences of our study with more common GWAS designs warrant mention. First, al-
though we performed standard chip-based genotyping as in other GWAS designs, we used a
nested case-control design for efficiency within the very large parent cohorts. This has the ad-
vantage of preserving power to detect associations with CHD with efficiency and produces un-
biased and reasonably precise estimates of relative risk comparable to what would be achieved
with a GWAS of the full cohorts of NHS or HPFS (because we genotyped all of the cases that
would have been present in the full cohort). While power to examine associations on biomark-
ers was not as efficiently maintained (because the case-control design explicitly tests a single
case definition or endpoint), even those associations had ample precision in our analyses be-
cause of their continuous distribution.
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Second, we did not conduct an unbiased effort to identify single, specific loci that influence
risk of CHD or its risk factors, as occurs in most GWAS. Rather, we tested a specific, global hy-
pothesis about the benefit of widespread variation across the genome. Had our hypothesis been
proven correct, the natural next step would be to search for specific loci at which that hypothe-
sis was borne out, more similar to standard GWAS efforts. As a consequence of our single un-
derlying hypothesis, however, our statistical analyses use conventional levels of statistical
significance and not the extreme thresholds more familiar in GWAS.
Our study has strengths, but important limitations as well. In both studies, participants who
provided blood were middle aged or older, and hence we did not study cases of CHD that oc-
curred early in life, which may be most closely associated with genetic factors, although our
findings in those below 65 years of age were also null. We also studied a geographically diverse
sample but occupationally homogeneous sample, in whom ascertainment of CHD is reliable
but who may not generalize readily to the full US population. We performed genome-wide
scans, and hence had an unbiased and comprehensive assessment of variation in SNPs, but we
cannot exclude the possibility that heterozygosity at specific loci (e.g., major histocompatibility
complex) or in other forms of genetic variation (e.g., copy number variants) favorably influence
CHD or its risk factors. Likewise, we studied CHD and its risk factors but cannot rule out asso-
ciations of heterozygosity with other chronic diseases nor with overall survival.
Power is an important concern in studies of heterozygosity. Number or proportion of het-
erozygous SNPs are an imperfect estimate of inbreeding,[23] potentially requiring large sam-
ples to overcome. Further, we were limited to case-control samples of moderate size with
narrow ranges in heterozygosity, illustrated by the small standard deviation in number of het-
erozygous loci relative to the number genotyped. Nonetheless, our point estimates demonstrat-
ed no association whatsoever with CHD risk, and our study compares favorably in size to the
Framingham Heart Study, which showed a significant association with blood pressure. Studies
in more inbred populations are needed to rule out associations with lower levels of heterozy-
gosity; at the extreme, consanguinity, which maximally suppresses heterozygosity, has been as-
sociated with CHD.[24] Equally, studies in populations in other ethnicities are warranted, as
populations of African descent in particular are apt to exhibit variability at substantially larger
numbers of loci.
In conclusion, in two cohort studies, genome-wide measures of heterozygosity were not as-
sociated with risk of incident CHD nor with CHD risk factors. If generalized heterozygosity
provides any fitness advantage in humans, it seems unlikely to do so for chronic disease pheno-
types like CHD at the levels of outbreeding seen in populations like these.
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